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ABSTRACT
Introduction: Individualizing glycemic targets
to goals of care and time to benefit in persons
with type 2 diabetes is good practice,
particularly in populations at risk of
hypoglycemia and adverse outcomes relating
to the use of antihyperglycemics. Guidelines
acknowledge the need for relaxed targets in frail
older adults, but there is little guidance on how
to safely deprescribe (i.e. stop, reduce or
substitute) antihyperglycemics.
Methods: The purpose of this study was to
synthesize evidence from all studies evaluating
the effects of deprescribing versus continuing
antihyperglycemics in older adults with type 2
diabetes. To this end, we searched MEDLINE,
EMBASE, and Cochrane Library (July 2015) for
controlled studies evaluating the effects of
deprescribing antihyperglycemics in adults
with type 2 diabetes. All such studies were
eligible for inclusion in our study, and two
independent reviewers screened titles, abstracts
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and full-text articles, extracted data, and
evaluated risk of bias. Grading of
Recommendations Assessment, Development
and Evaluation (GRADE) assessment and a
narrative summary were completed.
Results: We identified two controlled
before-and-after studies, both of very low
quality. One study found that an educational
intervention decreased glyburide use while not
compromising glucose control. The other
reported that cessation of antihyperglycemics
in elderly nursing home patients resulted in a
non-significant increase in glycated
hemoglobin (HbA1C). No significant change
in hypoglycemia rate was found in the only
study with this outcome measure.
Conclusions: There is limited evidence
available regarding deprescribing
antihyperglycemic medications. Adequately
powered, high-quality studies, particularly in
the elderly and with clinically important
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INTRODUCTION
Due to uncertainty regarding the benefits of
intensive glycemic control in older persons,
and the potential for harm from
overtreatment in this population [1],
organizations such as the Canadian Diabetes
Association suggest a glycated hemoglobin
(HbA1C) level of \8–8.5% in frail older
adults as an appropriate target (consensus
based) [2]. In older adults with diabetes, it is
often unclear whether reducing glucose
achieves meaningful risk reduction or
prevents complications of hyperglycemia.
Aggressive glycemic control has been
questioned in the frail elderly and those
with limited life expectancy, and adverse
effects such as hypoglycemia are of concern
[3, 4].
Despite efforts to reduce the risk of
hypoglycemia in the elderly by relaxing
glycemic control, there is little information on
how to deprescribe, which includes reducing
the dose or stopping/switching
antihyperglycemic medications in order to
individualize HbA1C targets. Clinicians are
aware that relaxed glycemic targets may be
appropriate in older patients, but they require
guidance to assist with deprescribing [5]. To
address this knowledge gap, we conducted a
systematic review to identify studies that have
evaluated the benefits and harms of
deprescribing antihyperglycemics in adults
with type 2 diabetes (T2DM).
METHODS
Our protocol was registered in PROSPERO
(CRD42015025727). We followed PRISMA
guidelines [6]. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Data Sources and Searches
MEDLINE (1946 onward), EMBASE (1947
onward), and the Cochrane Library through to
July 2015 were searched for relevant studies.
The references of relevant studies were scanned.
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In addition, we searched clinicaltrials.gov, the
World Health Organization Clinical Trials
Registry, UpToDate, and Google Scholar. There
was no limitation based on language. The
search strategy can be found in Electronic
Supplementary Material (ESM) Appendix 1.
Study Selection
Relevant studies included those involving
patients aged C18 years who were taking
antihyperglycemic medications for T2DM in
any setting. For inclusion in our analysis, the
following study designs were eligible, with no
minimum follow-up time or sample size:
randomized controlled trials, controlled
before–after studies, interrupted time series,
case–control studies, and prospective and
retrospective cohort studies. Included studies
compared the spectrum of deprescribing
approaches (stopping drug treatment entirely,
reducing dose, gradual tapering, or substitution)
of at least one medication (insulin, metformin,
sulfonylureas, thiazolidinediones, meglitinides,
alpha-glucosidase inhibitors, dipeptidyl
peptidase IV inhibitors, pramlintide,
glucagon-like peptide-1 agonists) to continuing
these medications. Included studies had to
report on at least one of the following:
hypoglycemia, falls, adverse drug reactions,
frequency of blood glucose testing, blood
glucose levels, HbA1C levels, pill burden,
emergency room visits and hospitalizations,
quality of life and patient satisfaction, length of
stay in hospital, microvascular complications,
macrovascular outcomes, polyuria,
hyperglycemia, and/or sleep disturbances.
Data Extraction and Quality Assessment
Two independent reviewers screened titles and
abstracts and evaluated full-text articles against
eligibility criteria. The reviewers independently
extracted data from eligible articles using a
pilot-tested form. We extracted the following:
year, journal, funding, study design, number of
participants, proportion of male/female
participants, comorbidities, duration of
diabetes, concomitant medications, study
medications, doses, frequency, duration and
stopping/tapering/switching regimen and
outcomes on benefits and harms of
deprescribing.
Data Synthesis and Analysis
Two independent reviewers conducted risk of
bias assessments for eligible studies using
Cochrane’s ROBINS-I tool [7]. We conducted a
narrative synthesis of results, using methods
described in our registered protocol [8]. Grading
of Recommendations Assessment, Development
and Evaluation (GRADE) was used to assess
quality of evidence [9].
RESULTS
Study Selection
Our search generated 3458 titles after
de-duplication. We evaluated 42 full-text
articles and two articles met the eligibility
criteria forqualitative synthesis [10, 11]. The
PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow
diagram is displayed in Fig. 1.
Study Characteristics and Risk of Bias
The first of the controlled before-and-after
studies which we identified as meeting the
inclusion criteria was that of Aspinall et al.
[11] who investigated deprescribing glyburide
(discontinuing glyburide and either switching
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to an alternative agent or not adding additional
medication to the therapeutic regimen) in
American community-dwelling older adults via
an educational intervention delivered to
pharmacists (see Table 1). The second such
study, by Sjo¨blom et al. [10], investigated the
withdrawal of all antihyperglycemics (or a
reduction of insulin) versus continuing
antihyperglycemics in Swedish nursing home
patients. The full study characteristics are
outlined in Table 1.
Both studies were judged to be at serious risk
of bias for all outcomes according to ROBINS-I
tool [7] due to important problems with
confounding, selection of participants, and
deviations from intended interventions (ESM
Appendices 2, 3).
Narrative Summary of Eligible Studies
In the study by Aspinall et al. [11], patients in
the intervention group were more likely to stop
glyburide [relative risk (RR) 1.28; 95%
confidence interval (CI) 1.22–1.33] compared
to those in the control group. The change in
HbA1C levels from baseline to
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Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ﬂow diagram
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post-intervention was compared in patients
who continued glyburide to those who
discontinued glyburide and did not start
another medication. No significant difference
in HbA1C levels was found between the group
of patients who discontinued glyburide and
those who continued taking this medication
(A1C increased by 0.04% in those who
discontinued glyburide vs. 0.06% in those who
continued; mean difference 0.02% lower; 95%
CI: -0.16 to 0.12%). In addition, no significant
difference was observed in the rates of
Table 1 Characteristics of eligible studies
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hypoglycemia post-intervention between the
intervention and control groups (RR 1.08; 95%
CI 0.78–1.50). A change in HbA1C level was
reported for patients (n = 999) who switched
from glyburide to alternative medications, for
whom HbA1C levels before and after the
intervention were 7.29% [standard deviation
(SD) 1.37%] and 7.33% (SD 1.41%),
respectively. Of these patients, 87% (874/999)
were switched to glipizide. A complete
summary of findings is provided in ESM
Appendix 4.
Sjo¨blom et al. [10] reported a non-significant
increase in HbA1C level for the intervention
group following deprescribing (mean difference
1.10%; 95% CI 0.56% lower to 1.64% higher).
There was no significant difference in the risk of
all-cause mortality for the deprescribing group
compared to the control group (RR 0.74; 95% CI
0.29–1.87). A complete summary of the findings
is provided in ESM Appendix 5.
Quality of Evidence
Based on the GRADE rating system, the quality
of evidence for both studies was very low due to
their non-randomized design and concerns
surrounding the risk of bias and imprecision.
GRADE evidence tables are given in ESM
Appendices 4 and 5.
DISCUSSION
Summary
Our systematic review identified two studies
which assessed deprescribing
antihyperglycemics in elderly patients. One
trial involved a group of community-dwelling
and predominantly male elderly patients with a
baseline HbA1C level of approximately 7.2%
[11]. Deprescribing glyburide in these patients
does not appear to adversely affect glucose
control, suggesting that an educational
intervention aimed at pharmacists may reduce
glyburide use without compromising glucose
control. However, the quality of evidence of
this study is very low. Although glyburide is
associated with hypoglycemia and poses a
higher risk than do other sulfonylureas [12],
deprescribing of glyburide does not appear to
reduce hypoglycemic events.
The second trial involved patients in 17
different nursing homes in Sweden [10]. Of
these patients, 75% (24/32) remained in the
intervention group after 3 months, with four
patients withdrawn due to hyperglycemia. The
results of this study demonstrate that frail
elderly patients are often treated to well below
the HbA1C targets and that deprescribing is
possible in the majority of patients without a
large impact on HbA1C levels (increase of 0.6%
after 6 months in intervention group to an
HbA1C level of 5.8%). Hypoglycemic events
were not reported.
These studies suggest that the deprescribing
of antihyperglycemics in older people is a
feasible strategy and may not compromise
blood glucose control or lead to clinically
significant increases in HbA1C levels, albeit
the published evidence is of very low quality.
Comparison to Existing Literature
A 2015 retrospective cohort study demonstrated
that deintensification of diabetes therapy is
attempted in around 20–30% of patients with
low HbA1C levels [13]. However, this study did
not report clinical outcomes of
deintensification. A 2011 retrospective analysis
of predominantly male elderly patients with
renal impairment (creatinine clearance\50 mL/
min) investigated the effect of switching from
glyburide to glipizide (uncontrolled before–after
28 Diabetes Ther (2017) 8:23–31
study) [14]. Despite an increase in HbA1C level
of 0.34% at 1 year, rates of hypoglycemia fell
from 31 to 13%. These results suggest that
hypoglycemia may be reduced following a
switch to sulfonylureas with a lower risk of
hypoglycemia and are consistent with
meta-analysis data suggesting that glyburide
carries an elevated risk of hypoglycemia
compared to glipizide [12].
Future Research
Our findings signal a need for adequately
powered high-quality antihyperglycemic
deprescribing studies in the elderly population
with T2DM—particularly in those populations
affected by new guidelines recommending
relaxed glycemic targets, with attention to the
design of features that minimize the risk of bias.
Randomized trials could be designed to compare
deprescribing protocols to usual care since there
is genuine clinical equipoise about the risks and
benefits of these strategies, and this would be the
least susceptible to selection bias.
Non-randomized studies could be designed to
compare those patients who have stopped or
received tapered medication with those who
continued, using established methods to
minimize risk of bias due to confounding.
Patients and their prescribers should engage in
shared decision-making regarding whether to
continue or deprescribe their antihyperglycemic
medication. Different deprescribing approaches
(e.g., tapering vs. abruptly discontinuing
antihyperglycemics, the effect of deprescribing
specific medications) should be studied.
Patient-important outcomes, such as
hypoglycemia rates, burden of treatment,
quality of life, and function, as well as
cost-effectiveness outcomes, should be
measured.
Strengths and Limitations
We used rigorous systematic review
methodology [6, 15] and GRADE to assess the
quality of evidence. However, only two studies
of very low quality were identified. We found
limited outcome data in the eligible studies and
a lack of patient-important outcomes. The
Aspinall et al. study [11], while large, only
provides evidence related to deprescribing
glyburide; and may not apply to patients on
other antihyperglycemics. Neither study [10,
11] provided practical information to assist
clinicians in deprescribing.
CONCLUSION
The evidence needed to guide clinicians in
helping patients achieve relaxed glycemic
targets through deprescribing is currently
lacking. While our systematic review suggests
deprescribing approaches may be feasible and
safe, we found no evidence of benefit or reduced
harm. Adequately powered high-quality studies
of deprescribing antihyperglycemics with
patient-important outcomes are required to
support evidence-based decision-making.
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